Table 3. Baseline characteristics of the subset of subjects with 1α-hydroxylase protein expression according to study group.
| Placebo (n = 8) |
Allopurinol (n = 20) |
|
|---|---|---|
| Age (years) | 57.5 ± 9.4 | 54.8 ± 15.7 |
| Gender (Male) | 4 (50%) | 8 (66.7%) |
| CKD-epi eGFR (mL/min/1.73m2) | 41.4 ± 12.4 | 39.0 ± 11.2 |
| Calcium (mg/dL) | 9.3 ± 0.3 | 9.0 ± 0.4 |
| Phosphorus (mg/dL) | 3.5 ± 0.7 | 3.5 ± 0.8 |
| 25 vitamin D (ng/mL) | 3.3 ± 0.3 | 3.2 ± 0.2 |
| Total 1,25 vitamin D (pg/mL) | 3.1 ± 0.5 | 3.1 ± 0.5 |
| 24,25 vitamin D (pg/mL) | 0.9 ± 0.7 | 0.4 ± 1.2 |
| iPTH (pg/mL) | 83.6 ± 38.7 | 81.0 ± 24.2 |
| FGF-23 (pg/mL)-Median (IQR) | 110.4 (28.9, 470.4) | 74.1 (28.1, 151.2) |
| 1α-hydroxylase | 0.7 ± 0.3 | 0.8 ± 0.2 |
Values are expressed as means ± standard deviation, median (interquartile range), or % = percent of patients; iPTH = intact parathyroid hormone; FGF-23 = fibroblast growth factor-23